0001104659-12-032075.txt : 20120502 0001104659-12-032075.hdr.sgml : 20120502 20120502170543 ACCESSION NUMBER: 0001104659-12-032075 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20120430 FILED AS OF DATE: 20120502 DATE AS OF CHANGE: 20120502 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CAVAZZA PAOLO CENTRAL INDEX KEY: 0001163608 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19825 FILM NUMBER: 12806223 MAIL ADDRESS: STREET 1: VIA TESSERETE, 10 CITY: LUGANO STATE: V8 ZIP: V8 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 BUSINESS PHONE: 650-358-3456 MAIL ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 4 1 a4.xml 4 X0305 4 2012-04-30 1 0000880771 SCICLONE PHARMACEUTICALS INC SCLN 0001163608 CAVAZZA PAOLO VIA TESSERETE 10 LUGANO V8 00000 SWITZERLAND 0 0 1 0 Common Stock 2012-04-30 4 S 0 6328469 5.25 D 252469 I I Common Stock 2012-04-30 4 D 0 252469 5.25 D 0 I I Common Stock 2012-04-30 4 D 0 252469 5.25 D 513372 I I Common Stock 2012-04-30 4 D 0 147531 5.25 D 1141521 I I Common Stock 822815 D Shares directly owned by Defiante Farmaceutica S.A. ("Defiante"). Defiante is 58% directly owned by Sigma-Tau Finanziaria S.p.A. ("Sigma-Tau") and 42% directly owned by Sigma-Tau's wholly-owned subsidiary Sigma-Tau International S.A. Paolo Cavazza directly and indirectly owns 38% of Sigma-Tau. Shares directly owned by Aptafin S.p.A. ("Aptafin"). Aptafin is owned by Paolo Cavazza and members of his family. Shares directly owned by Sinaf S.A. ("Sinaf"). Sinaf is 100% directly owned by Aptafin. Exhibit List Exhibit 24 - Power of Attorney, dated February 29, 2008, by Paolo Cavazza /s/ Fabio Poma, Attorney-in-fact 2012-05-02 EX-24 2 ex-24.htm EX-24

Exhibit 24

 

POWER OF ATTORNEY

 

Each of the undersigned does hereby constitute and appoint each of Fabio Poma, Rocco Nava and Nicola Wullschleger, with full power of substitution, as the true and lawful attorney-in-fact and agent of the undersigned, and authorizes and designates each of the foregoing attorneys-in-fact to sign on behalf of the undersigned, and to file filings and any amendments thereto, with the Securities and Exchange Commission, made by or on behalf of the undersigned in respect of (i) the beneficial ownership of equity securities of SciClone Pharmaceuticals, Inc. held by the undersigned, directly, indirectly or beneficially, pursuant to Sections 13(d), 13(g) and 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations thereunder and (ii) the disposition of equity securities of SciClone Pharmaceuticals, Inc. held by the undersigned, directly, indirectly or beneficially, in accordance with Rule 144 of the Securities Act of 1933, as amended (the “Securities Act”), and the rules and regulations thereunder, including the filing of any Form 144 pursuant to the Securities Act.  Each of the undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of each of the undersigned, are not assuming any of the undersigned’s responsibilities to comply with Sections 13(d), 13(g) or 16 of the Exchange Act or Rule 144 of the Securities Act.

 

This Power of Attorney shall remain in full force and effect until withdrawn by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

 

IN WITNESS WHEREOF, each of the undersigned has caused this Power of Attorney to be executed as of this 29th day of February, 2008.

 

 

/s/ Paolo Cavazza

 

Paolo Cavazza